Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26533737 | 1.00 | KDM4E (0.30) | KDM4EMEN1ALDH1A1HPGDHTT | |
| SCHEMBL26114057 | 0.96 | — | — | |
| SCHEMBL30776456 | 0.91 | RORC (0.31) | ALDH1A1HPGDHTT | |
| SCHEMBL26535186 | 0.91 | RORC (0.31) | ALDH1A1HPGDHTT | |
| SCHEMBL30587224 | 0.89 | THRB (0.31) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL26114998 | 0.89 | THRB (0.31) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL30587198 | 0.89 | THRB (0.31) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL31278508 | 0.89 | THRB (0.31) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL26115041 | 0.89 | THRB (0.31) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL27084115 | 0.87 | RORC (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 2640/4885MEN1 226/4885ALDH1A1 1852/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | KDM4E 2640/4885MEN1 226/4885ALDH1A1 1852/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 2640/4885MEN1 226/4885ALDH1A1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.